Literature DB >> 15194218

Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells.

Hiroaki Toshimitsu1, Kiichiro Hashimoto, Akira Tangoku, Norio Iizuka, Kohtaro Yamamoto, Shigeto Kawauchi, Atsunori Oga, Tomoko Furuya, Masaaki Oka, Kohsuke Sasaki.   

Abstract

To clarify the molecular basis of acquired cisplatin (CDDP) resistance in esophageal squamous cell carcinoma (ESCC), we used cDNA microarray technology. A CDDP-resistant cell line (YES-2/CDDP), which shows a 7.5-fold increase in resistance to CDDP and a 3-fold decrease in CDDP accumulation compared with the parental YES-2 ESCC cell line, was generated from YES-2 by exposure to increased concentrations of CDDP. By cDNA microarray analysis, we identified 44 genes with significantly different expression levels between YES-2/CDDP and YES-2 cells. Interestingly, 15 of these 44 genes encoded ribosome-related proteins, almost all of which were underexpressed in YES-2/CDDP cells. Our present data suggest that many ribosome-related genes may be involved in the acquired resistance to CDDP in ESCC and that such information may allow us to better understand the mechanism of CDDP resistance. Copyright 2004 Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194218     DOI: 10.1016/j.canlet.2004.01.038

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

Review 1.  cDNA microarray analysis of esophageal cancer: discoveries and prospects.

Authors:  Yutaka Shimada; Fumiaki Sato; Kazuharu Shimizu; Gozoh Tsujimoto; Kazuhiro Tsukada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-07-14

2.  Current gene expression studies in esophageal carcinoma.

Authors:  Wei Guo; Yao-Guang Jiang
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

3.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10

4.  Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells.

Authors:  Juan D Chavez; Michael R Hoopmann; Chad R Weisbrod; Kohji Takara; James E Bruce
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

5.  Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells.

Authors:  Le Yu; William K K Wu; Chunping Gu; Desheng Zhong; Xuyan Zhao; Yi Kong; Qinghuan Lin; Matthew T V Chan; Zhitao Zhou; Shuwen Liu
Journal:  Oncotarget       Date:  2016-03-22

6.  Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach.

Authors:  Navin Sarin; Florian Engel; Florian Rothweiler; Jindrich Cinatl; Martin Michaelis; Roland Frötschl; Holger Fröhlich; Ganna V Kalayda
Journal:  Int J Mol Sci       Date:  2018-03-07       Impact factor: 5.923

7.  The ginsenoside Rk3 exerts anti-esophageal cancer activity in vitro and in vivo by mediating apoptosis and autophagy through regulation of the PI3K/Akt/mTOR pathway.

Authors:  Huanhuan Liu; Jiaqi Zhao; Rongzhan Fu; Chenhui Zhu; Daidi Fan
Journal:  PLoS One       Date:  2019-05-15       Impact factor: 3.240

8.  Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.

Authors:  Katsuhiro Uzawa; Atsushi Kasamatsu; Takao Baba; Katsuya Usukura; Yasuhiro Saito; Kentaro Sakuma; Manabu Iyoda; Yosuke Sakamoto; Katsunori Ogawara; Masashi Shiiba; Hideki Tanzawa
Journal:  Cancer Med       Date:  2013-02-03       Impact factor: 4.452

9.  Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.

Authors:  Si Sun; Simei Zhao; Qiang Yang; Wenwen Wang; E Cai; Yiping Wen; Lili Yu; Zehua Wang; Jing Cai
Journal:  Cancer Sci       Date:  2018-05-15       Impact factor: 6.716

10.  Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma.

Authors:  Dessy Chan; Yuanyuan Zhou; Chung Hin Chui; Kim Hung Lam; Simon Law; Albert Sun-Chi Chan; Xingshu Li; Alfred King-Yin Lam; Johnny Cheuk On Tang
Journal:  Cells       Date:  2018-09-20       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.